Vikipediya

Pfizer–BioNTech COVID-19 vaksini

(Pfizer–BioNTech Covid-19 vaksini səhifəsindən yönləndirilmişdir)

ComiRNAty brendi altında satılan[1][2] Pfizer–BioNTech COVID-19 peyvəndi (INN: tozinaran), Almaniyanın BioNTech biotexnologiya şirkəti tərəfindən hazırlanmış və onun hazırlanmasında klinik sınaqlar, logistika və istehsal dəstəyi üçün Amerika şirkəti Pfizer ilə əməkdaşlıq edən mRNT əsaslı COVID-19 peyvəndidir.[3][4] Peyvənd əzələdaxili inyeksiya yolu ilə verilir. O, lipid nanohissəcikləri ilə əhatə olunmuş SARS-CoV-2-nin tam uzunluqlu sünbül zülalının mutasiya edilmiş formasını kodlayan nukleozidlə dəyişdirilmiş mRNT-dən (modRNT) ibarətdir.[5] İlkin tövsiyədə peyvəndin 21 gün ara ilə[6][7][8][9] iki dozada verilməli olduğu bildirilmişdi, lakin sonradan bu interval ABŞ-da 42 günə[6][10], Kanadada isə dörd aya qədər uzadıldı.[11][12]

ABŞ bazarı üçün Pfizer–BioNTech COVID‑19 peyvəndi flakonu

İstinadlar

redaktə
  1. ↑ "ComiRNTty EPAR"[ölü keçid]. European Medicines Agency (EMA). Retrieved 24 October 2021.
  2. ↑ "FDA Approves First COVID-19 Vaccine" (Press release). U.S. Food and Drug Administration (FDA). 23 August 2021. Archived from the original on 23 August 2021. Retrieved 23 August 2021.
  3. ↑ Browne R (11 November 2020). "What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine". CNBC. Archived from the original on 4 March 2021. Retrieved 14 January 2021.
  4. ↑ Thomas K, Gelles D, Zimmer C (9 November 2020). "Pfizer's early data shows vaccine is more than 90% effective". The New York Times. Archived from the original on 23 November 2020. Retrieved 9 November 2020.
  5. ↑ Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. (October 2020). "Safety and Immunogenicity of Two RNT-Based Covid-19 Vaccine Candidates". The New England JouRNTl of Medicine. 383 (25): 2439–50. doi:10.1056/NEJMoa2027906. PMC 7583697. PMID 33053279.
  6. ↑ 1 2 "Pfizer–BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 12 Years of Age and Older" Arxivləşdirilib 2021-03-02 at the Wayback Machine (PDF). U.S. Centers for Disease Control and Prevention (CDC). 28 September 2021. Retrieved 24 October 2021.
  7. ↑ "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNT Vaccine Candidates Against COVID-19 in Healthy Individuals". ClinicalTrials.gov. 30 April 2020. Archived from the original on 11 October 2020. Retrieved 5 August 2021.
  8. ↑ Palca J (9 November 2020). "Pfizer says experimental COVID-19 vaccine is more than 90% effective". NPR.org. NPR. Archived from the original on 9 November 2020. Retrieved 9 November 2020.
  9. ↑ Herper M (9 November 2020). "Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate". Stat News. Archived from the original on 9 November 2020. Retrieved 9 November 2020.
  10. ↑ Ellis R. "CDC: Gap Between Vaccine Doses Could Be 6 Weeks". WebMD. Archived from the original on 4 may 2021. Retrieved 8 July 2021.
  11. ↑ "Canada vaccine panel recommends 4 months between COVID doses". ABC News. 4 March 2021. Archived from the original on 26 July 2021. Retrieved 9 July 2021.
  12. ↑ Public Health Agency of Canada (2 July 2021). Recommendations on the use of COVID-19 vaccines (PDF). Health Canada (Report). Archived (PDF) from the original on 23 June 2021. Retrieved 9 July 2021.
Mənbə — "https://az.wikipedia.org/w/index.php?title=Pfizer–BioNTech_COVID-19_vaksini&oldid=7748547"